Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice.

European journal of immunology - 1 Jun 2015

Liu Qian, Li Zhanzhuo, Gao Ji-Liang, Wan Wuzhou, Ganesan Sundar, McDermott David H, Murphy Philip M

Abstract excerpt

AMD3100 (plerixafor), is a specific CXCR4 antagonist approved by the FDA for mobilizing hematopoietic stem cells from bone marrow to blood for transplantation in cancer. AMD3100 also mobilizes most mature leukocyte subsets to blood; however, their source and trafficking potential have not been fully delineated. Here, we show that a single injection of AMD3100 10 mg/kg into C57Bl/6 mice rapidly mobilizes (peak ∼...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzylamines
Share to Heterocyclic Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Leukocytes

Share to Lymph Nodes

Share to Receptors, CXCR4

Share to T-Lymphocyte Subsets

Share to Thymus Gland

Source

Open in PubMed Open full text

Identifiers

PMID: 25801950
DOI: 10.1002/eji.201445245
PMCID: PMC4461468

Genes

CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice.PMID 25801950Read ↗

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistSemantic proximity Read ↗

Neutrophil mobilization via plerixafor-mediated CXCR4 inhibition arises from lung demargination and blockade of neutrophil homing to the bone marrow.Semantic proximity Read ↗

CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease.Semantic proximity Read ↗

The Monocytes That Repopulate in Mice After Cyclophosphamide Treatment Acquire a Neutrophil Precursor Gene Signature and Immunosuppressive ActivitySemantic proximity Read ↗

Cytotoxic CD4 <sup>+</sup> T cells in the bone marrow compromise healthy ageing by enhancing granulopoiesisSemantic proximity Read ↗

AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primatesSemantic proximity Read ↗

Sexual dimorphisms in leukocyte trafficking in a mouse peritonitis modelSemantic proximity Read ↗

Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow <i>in vivo</i> according to their ability to inhibit CXCL12 binding to CXCR4 <i>in vitro</i>Semantic proximity Read ↗

Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 AntibodySemantic proximity Read ↗

Cytokines and hematopoietic stem cell mobilization.Semantic proximity Read ↗

Characterization of CD34+ cells mobilized to the peripheral blood during the recovery from cyclophosphamide chemotherapy.Semantic proximity Read ↗

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.